- A study of 2.3 million patients found mRNA COVID-19 vaccine recipients had a 30% higher risk of thyroid disorders (e.g., hypothyroidism) compared to unvaccinated individuals, with over 4,000 extra hypothyroidism cases observed. Those who received only one dose faced double the risk.
- The study suggests mRNA vaccines may trigger autoimmune reactions, where the immune system attacks thyroid tissue, mirroring concerns seen with other conditions like myocarditis and hepatitis. The Johnson & Johnson vaccine (non-mRNA) showed no elevated thyroid risks, pointing to mRNA-specific effects.
- Thyroid dysfunction can lead to chronic metabolic issues (weight gain, high cholesterol, cardiovascular stress). Researchers warn of slow-progressing symptoms that may be overlooked, emphasizing the need for post-vaccination thyroid monitoring.
- Despite robust methodology (1.16 million vaccinated vs. unvaccinated matched controls), the study received little mainstream attention, reflecting broader challenges in addressing vaccine safety concerns transparently.
- The findings highlight the need for long-term safety evaluations of mRNA technology, especially as it expands into annual boosters and flu vaccines. Critics argue crisis-driven approvals bypassed standard long-term trials, risking unintended health consequences.
(Natural News)—A groundbreaking study of over 2.3 million patients has found that recipients of mRNA-based COVID-19 vaccines face a significantly higher risk of developing thyroid disease than unvaccinated individuals, raising urgent questions about the lasting health consequences of pandemic-era shots. Published in January 2024 but only recently highlighted by researchers, the analysis—led by scientists at National Taiwan University—reveals that vaccinated individuals were 30% likelier to be diagnosed with thyroid disorders a year later, with over 4,000 extra cases of hypothyroidism alone in the study group. Even more striking, people who received only one dose of an mRNA vaccine had nearly double the risk of hypothyroidism compared to unvaccinated peers. These findings add urgency to ongoing debates about the long-term safety of mRNA technology amid a growing body of research linking vaccines to autoimmune conditions, including myocarditis and hepatitis.
The study’s key findings: A statistical wake-up call
The Taiwanese researchers used the TriNetX medical records database, covering 116 million patients, to track outcomes for 1.16 million vaccinated individuals and an equal number of unvaccinated, medically matched controls from January 2022 to December 2023. The results were stark:
- Hypothyroidism risks: Over 4,000 extra cases of hypothyroidism were observed in the vaccinated group after one year, with hazard ratios (a measure of relative risk) ranging from 1.14 to 1.30 for the condition. The gap between vaccinated and unvaccinated patients widened steadily over time.
- Hyperthyroidism paradox: While vaccinated individuals initially showed reduced hyperthyroidism rates between 3–9 months post-vaccination, this trend faded by 12 months, suggesting transient suppression followed by later complications. Among mRNA recipients specifically, hyperthyroidism risks also rose at 12 months, indicating further complexity.
- Single-dose subgroup: Those who received only one mRNA dose faced the highest risks, with hypothyroidism cases doubling and hyperthyroidism increasing by 25%. This finding may reflect heightened immune responses in persons less likely to tolerate multiple injections.
Lead author Dr. Chen-Min Liang, a thyroid specialist at National Taiwan University, emphasized the statistical rigor of the study: “Our sample size and matching protocols minimized confounding factors. These risks are unlikely coincidental.” The study also compared outcomes for recipients of the lesser-studied Johnson & Johnson (Ad26) vaccine, which did not correlate with elevated thyroid risks, strengthening suspicions about mRNA-specific mechanisms.
Autoimmune concerns and broader implications
The thyroid’s role in regulating metabolism makes even moderate dysfunction a hidden health drain, sapping energy and contributing to weight gain, high cholesterol and cardiovascular stress. The study’s authors note that mRNA vaccines, which instruct immune cells to produce SARS-CoV-2 spike proteins, may trigger autoimmune reactions — where the immune system mistakenly targets bodily tissues — such as those seen in multiple sclerosis, Type 1 diabetes and hypothyroidism.
This thyroid data follows years of scattered reports associating mRNA shots with autoimmune hepatitis, myocarditis and rare neurological disorders. The U.S. Centers for Disease Control and Prevention (CDC), for instance, has acknowledged a “high verification rate” of myocarditis cases after mRNA vaccinations, with higher risks noted for adolescents and young adults. Such harms, critics argue, justify closer scrutiny of population-level post-vaccination outcomes.
Dr. Patricia Fitzgerald, an immunologist at the University of California, San Francisco, who was not involved in the study, noted: “The thyroid is a classic target in autoimmune disorders. If mRNA mechanisms prime the immune system to cross-react with thyroid tissue, that’s a red flag for chronic health impacts.”
A call for vigilance in an era of scientific uncertainty
The Taiwanese study’s near-total obscurity in mainstream media highlights both the challenges of communicating difficult science and the uneven playing field facing researchers who question vaccine safety. As of May 2025, the paper had received limited attention despite its publication in a major journal — a pattern authors attribute to systemic reluctance to scrutinize widely deployed public health tools.
Meanwhile, broader population trends hint at unsolved puzzles. Data from the CDC and other agencies show elevated mortality in several high-income nations with high mRNA uptake, even as pandemic deaths dwindle. While not definitively linked to vaccines, lingering autoimmune effects like thyroid dysfunction could contribute to such trends by worsening chronic conditions over years.
As nations grapple with mandates for annual booster shots and mRNA-based flu vaccines, the study underscores why transparency matters: Thyroid disorders often progress slowly, with symptoms dismissed as stress or aging before a definitive diagnosis. In that light, the researchers’ call for “ongoing thyroid function monitoring” after mRNA vaccination now feels less like a technical recommendation and more like a plea for caution.
The mRNA vaccine safety debate
The current controversy mirrors past public health disputes over vaccines and medications. The 1950s polio vaccine’s rollout, for instance, sparked early debates about rare but serious adverse events, spurring improvements in safety protocols. Similarly, modern mRNA technology’s rapid deployment during the pandemic sidestepped decades of standard pre-approval trials, leaving unresolved questions about long-term effects especially in non-pandemic settings.
Today’s studies, often published in obscure journals or sidelined by mainstream discourse, reflect a broader struggle over science communication. As more data emerge, the challenge becomes clear: Balancing pandemic-era urgency with the ethics of informed consent demands fearless scrutiny of mRNA’s collateral health costs, even as the world moves forward.
The unfinished journey toward vaccine transparency
This study does not condemn mRNA vaccines as inherently dangerous. But it does demand answers — especially given their now-widespread use beyond emergency settings. If thyroid risks emerge as just one facet of long-term immune disruption, future generations may look back on the 2020s as a moment when scientific humility collided with crisis-driven mandates. Whether openness prevails over complacency could determine how millions of lives unfold, one gland at a time.
Sources for this article include:
Bypass Big Tech Censors
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.